Rare fossa cubs born in Paris zoo as wild numbers shrink in Madagascar
The baby fossas were first shown to the public this month at the Paris Zoological Park in Vincennes. Many visitors will have never heard of the species, which looks a little like a small wild cat but is more closely related to mongooses.
'It looks like a mini tree-dwelling puma, with a tail that's about the same length as its body – maybe even a bit longer,' said zoo veterinarian Alexis Lécu.
Even in Madagascar, the fossa is hard to spot. Its forest habitat is shrinking every year due to farming and logging. Scientists believe that only around 3,000 fossas remain in the wild.
'Our visitors are often discovering this species for the first time. Even when you go to Madagascar, you see more lemurs than fossas,' Lécu said.
Wild chimpanzees beat the bush telegraph using tree-root rhythms
Elusive and under pressure
Fossas are difficult to study. 'They only comes from one island and are not a species that's spread out over a continent. Their whole system of hunting and lifestyle is based on hiding,' Lécu explained.
The species plays a key role in Madagascar's ecosystems, but is classed as vulnerable as human activity puts it at risk.
The cubs, born in May, are among just 10 fossas born in zoos around the world this year. Their arrival in Paris is seen as a success for global breeding efforts.
Staff at the zoo closely monitor the fossas' behaviour, rest and reproduction, sharing their findings with partners in Madagascar.
They are also working with local conservationists to protect the species in the wild. That includes helping people who depend on the island's forests for farming, firewood and food.
'The aim is to help local populations live – to find ways of making a living that work, while continuing to protect species like lemurs, fossas and reptiles,' Lécu said.
Zimbabwe's elephant boom fuels conflict alongside conservation wins
No return to the wild
The three cubs will eventually be sent to other zoos around the world as part of a breeding programme to help maintain a healthy global population.
But for now, there is no plan to reintroduce them into the wild.
Zoos like Vincennes are one of the few safe spaces left for fossas – and a reminder of what could be lost if Madagascar's forests continue to disappear.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
13 hours ago
- Medscape
Type II Vasculitis Signals Poor Prognosis in Sjögren Disease
TOPLINE: Among patients with primary Sjögren disease, type II cryoglobulinemic vasculitis is linked to an increased risk for lymphoma and mortality, a French study showed. METHODOLOGY: Researchers conducted a retrospective multicenter cohort study of 54 patients with primary Sjögren disease and cutaneous vasculitis (CV) from three pathology departments in Paris and a national case call in France (median age, 42 years; 91% women). Patients were diagnosed with CV between 2011 and 2021; 29 (57%) had cryoglobulinemic vasculitis and 15 (28%) had hypergammaglobulinemic vasculitis; 24 of the 29 cryoglobulinemic cases were type II. Data were analyzed between March 2023 and March 2025. Patients were matched 1:2 to 108 controls with Sjögren disease but without CV from the French ASSESS cohort. Primary outcomes of the study were the occurrence of lymphoma diagnosis and mortality risk. TAKEAWAY: Patients with Sjögren disease and CV showed a higher lymphoma incidence than those without CV (13% vs 4%; P = .04). Patients with type II cryoglobulinemic vasculitis had a significantly higher incidence of lymphoma (21% vs 0%; P = .02) and increased mortality (29% vs 0; P = .02) than those with other types of small-vessel vasculitis. The risk for death or non-Hodgkin lymphoma was increased by nearly sevenfold risk in patients with type II cryoglobulinemic vasculitis (hazard ratio [HR], 6.8; P = .005) compared with other CV types. Patients with type II cryoglobulinemic vasculitis were more likely to have subacute cutaneous lupus (21% vs 0%; P = .02), kidney involvement (29% vs 4%; P = .02) and peripheral nervous system involvement (63% vs 12%; P < .001) than those with other CV types. Among 24 patients with type II cryoglobulinemic vasculitis, 12 received rituximab-based first-line treatment; non-Hodgkin lymphoma developed in 8% of patients in the rituximab group and in 25% of those who received other treatments, whereas mortality rates were 33% and 25%, respectively. IN PRACTICE: 'In this cohort study, among patients with CV-complicated Sjögren disease, only type II cryoglobulinemic vasculitis was associated with severe visceral involvement, higher risk of non-Hodgkin lymphoma, and mortality,' the study authors wrote. These findings, they added, highlighted the need for 'specific monitoring for these patients.' SOURCE: The study was led by Paul Breillat, MD, INSERM, Paris Centre de Recherche Cardiovasculaire, Paris, France, and was published online on August 6 in JAMA Dermatology. LIMITATIONS: The retrospective design and potential missing data could affect the interpretation of results. Additionally, half of the patients were diagnosed with CV on the basis of clinical criteria. DISCLOSURES: The ASSESS cohort was set up with a grant from the French Ministry of Health. One author reported receiving personal fees from Bristol Myers Squibb, GSK, Novartis, and Otsuka; another author reported receiving grants from AstraZeneca, Bristol Myers Squibb, and GSK. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Forbes
18 hours ago
- Forbes
Brazil's Hidden Hotspot For Silky Sharks Could Be A Lifeline
Beneath the crystal-clear, sun-dappled turquoise waters of Brazil's Alcatrazes Archipelago Wildlife Refuge, vibrant reefs shimmer and a variety of sea life thrives. El Refúgio de Vida Silvestre do Arquipélago de Alcatrazes, located off the southeastern coast of São Paulo, about 22 miles (35 kilometers) from the city of São Sebastião, is part of the Tupinambás Ecological Station and managed by the Chico Mendes Institute for Biodiversity Conservation (ICMBio). Consisting of more than a dozen islands, islets, and rocky outcrops, it serves as a critical habitat for over 1,300 marine and terrestrial species, many of which are endemic, rare, or threatened. Officially designated as a wildlife refuge in 2016, after years of military use and restricted public access, the surrounding waters are rich in biodiversity, home to reef fish, sea turtles, dolphins, rays, and various shark species. One of these species, it seems, is the silky shark (Carcharhinus falciformis). And when researchers observed witnessed an unexpected aggregation of 250 to 300 silky sharks in these protected waters off Brazil, it wasn't just a memorable field day… it's potentially a game-changer for shark conservation in the South Atlantic. Sleek, fast-moving predators found in warm ocean waters around the world, silky sharks are named for the smooth texture of their skin. Easily recognized by their slender bodies, long pectoral fins, and rounded snouts, this species is often seen cruising in the open ocean, particularly along the edges of continental shelves, around seamounts, and near offshore reefs. Silky sharks are highly migratory, but despite their wide range, silky sharks are facing serious conservation challenges; they are one of the most heavily fished shark species in the world, primarily because they are caught as bycatch in tuna fisheries or targeted for their fins, which are valuable in the shark fin trade. As a result, their populations have declined sharply in many areas. The International Union for Conservation of Nature lists them as Vulnerable, and in Brazil, they are classified as Critically Endangered. It's important to note that silky sharks aren't known to be particularly social. While they are not exactly loners, seeing them in such large numbers is… unusual. Aggregation sites can play a vital role in the species' life cycle, possibly linked to feeding, mating, or even giving birth. Yet, we know surprisingly little about where these gatherings occur or how often they happen. That's part of what makes this sighting so special: it's the first time such a large group has ever been documented in this part of the world! It hints that the Alcatrazes Archipelago, already a protected marine area, may be far more important to silky sharks than previously realized. This is especially true if there are aggregation sites for them here on more than just a one-off experience. Right now, we just don't know if it is or not, since the Alcatrazes sighting wasn't part of a planned survey and happened unexpectedly during a dive expedition. But that doesn't make it any less valuable since this kind of information is gold when it comes to crafting effective conservation strategies. Many marine species, especially large predators like sharks, depend on specific habitats at key points in their lives. If scientists can pinpoint and protect those places, we can give these animals a real fighting chance. Especially since aggregation areas can be hotspots for fishing activity too, which puts even more pressure on vulnerable species. Identifying a location where they come together in large numbers can help policymakers and marine managers make informed decisions (whether it's adjusting fishing zones, increasing surveillance, or enhancing legal protections). Accidentally stumbling over this aggregation allows for local conservation efforts to be fine-tuned, ensuring that the right places are getting the right levels of protection at the right time. In many ways, the discovery raises more questions than it answers. Why are the sharks aggregating here? Is this a seasonal event, or a one-time occurrence? Are they mating? Feeding? Resting in-between long stints of oceanic journeys? Long-term monitoring will be needed to understand what's really going on beneath the surface, but now that scientists know where to look, they can begin that work. And that's the first step toward making a real difference. Because for silky sharks, time is running out. Their populations cannot afford a continued decline, and conservation efforts need to move fast. And in the end, knowing where sharks go is just the beginning. Making sure they're safe when they get there? That's the real goal.
Yahoo
a day ago
- Yahoo
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. ('Vigil'). This acquisition strengthens Sanofi's early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer's disease. In addition, the acquisition of Vigil's preclinical pipeline will further strengthen Sanofi's research in various neurodegenerative diseases. In June 2024, Sanofi made a $40 million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. Under the terms of the acquisition agreement, Sanofi and Vigil have agreed to the following: Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis) In addition, Vigil's shareholders received a non-transferrable contingent value right (CVR) per Vigil share, which entitles its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG-3927. VGL101, Vigil's second clinical program, was not acquired by Sanofi. As previously communicated, the acquisition of Vigil is not expected to impact Sanofi's financial guidance for 2025. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data